Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported significant financial results for Q1 2020. The company achieved GAAP profitability with a net income of $0.5 million, contrasting a net loss of $9.7 million in Q1 2019. Non-GAAP net income reached $31.2 million. Xtampza ER prescriptions surged by 30% year-over-year. The company also closed the acquisition of Nucynta rights, which contributed positively to revenue growth. However, it revised its 2020 financial guidance due to COVID-19 impact, lowering expected revenues for Xtampza ER from $150-$160 million to $130-$140 million.